This retrospective study aims to assess the prognostic value and survival implications of the CPS+EG score in women diagnosed with HER2-positive breast cancer, regardless of hormone receptor status, who are undergoing neoadjuvant chemotherapy (NACT). The gene discussed is ERBB2; the disease is breast cancer.